SG11201811709WA - Compounds, compositions, and methods for the treatment of disease - Google Patents

Compounds, compositions, and methods for the treatment of disease

Info

Publication number
SG11201811709WA
SG11201811709WA SG11201811709WA SG11201811709WA SG11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA
Authority
SG
Singapore
Prior art keywords
international
shrewsbury
july
compositions
compounds
Prior art date
Application number
SG11201811709WA
Inventor
Radhakrishnan Iyer
Anjaneyulu Sheri
Seetharamaiyer Padmanabhan
Geeta Meher
Shenghua Zhou
Sreerupa Challa
Rayomand Gimi
Dillon Cleary
Original Assignee
Sperovie Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sperovie Biosciences Inc filed Critical Sperovie Biosciences Inc
Publication of SG11201811709WA publication Critical patent/SG11201811709WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 January 2018 (11.01.2018) WI P0 I PC T IiiimmomiolollmonoloololionolioommomovoimIE (10) International Publication Number WO 2018/009648 Al 00 71 O - LI- (51) International Patent Classification: A61K 31/7052 (2006.01) A61K 39/12 (2006.01) A61K 31/7084 (2006.01) (21) International Application Number: PCT/US2017/040882 (22) International Filing Date: 06 July 2017 (06.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/359,039 06 July 2016 (06.07.2016) US 62/363,118 15 July 2016 (15.07.2016) US 62/403,530 03 October 2016 (03.10.2016) US 62/411,424 21 October 2016 (21.10.2016) US 62/444,141 09 January 2017 (09.01.2017) US 62/462,679 23 February 2017 (23.02.2017) US 62/470,746 13 March 2017 (13.03.2017) US 62/508,846 19 May 2017 (19.05.2017) US (71) Applicant: SPEROVIE BIOSCIENCES, INC. [US/US]; 113 Cedar Street, Milford, MA 01757 (US). (72) Inventors: IYER, Radhakrishnan, P.; 15 Quail Hollow Drive, Shrewsbury, MA 01545 (US). SHERI, Anjaneyu- lu; 12 Pheasant Hill Drive, Shrewsbury, MA 01545 (US). PADMANABHAN, Seetharamaiyer; 67 Fottler Avenue, Lexington, MA 02420 (US). MEHER, Geeta; 4 Capital Road #1, Milford, MA 01757 (US). ZHOU, Shenghua; 21 Stoney Hill Road, Shrewsbury, MA 01545 (US). CHAL- LA, Sreerupa; 3132 Arbor Dr., Shrewsbury, MA 01545 (US). GIMI, Rayomand, H.; 41 Stonegate Road, Chelms- ford, MA 01824 (US). CLEARY, Dillon; 99 Spruce Street, Middleborough, MA 02346 (US). (74) Agent: GORDON, Dana, M. et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) (54) Title: COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE 10000 cn 'too 10 1 T ▪ ern iss ue c Cr, ...I- ix, ▪ co co co o CV CO CM CO P.- 0 0 0 CV Cr) ..er L0 CON-CO 0 0 CV CO \"V- CI_ C.1 CV CV CV CV CV CV CV CV CV CI CI Cr, Cr> EEEEEEEEEco_to-co_co_co_co_ C=L CL CL 0_ CL CL CL CL CL CL CL CL CL CL CL CLcD c)c..)c_3(_3(\"c_)c_3(_)c_)EeEEEEEEEEEEEEEEEEEEEEEEEc_a C-D C_D C_D CD C_D C-3 C-1. C-3 C-3 C-3 C-D c-3 c-D c-3 C.D C.D C-D C-D -ro FIG. 1A 25µM Compound O O (57) : Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
SG11201811709WA 2016-07-06 2017-07-06 Compounds, compositions, and methods for the treatment of disease SG11201811709WA (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662359039P 2016-07-06 2016-07-06
US201662363118P 2016-07-15 2016-07-15
US201662403530P 2016-10-03 2016-10-03
US201662411424P 2016-10-21 2016-10-21
US201762444141P 2017-01-09 2017-01-09
US201762462679P 2017-02-23 2017-02-23
US201762470746P 2017-03-13 2017-03-13
US201762508846P 2017-05-19 2017-05-19
PCT/US2017/040882 WO2018009648A1 (en) 2016-07-06 2017-07-06 Compounds, compositions, and methods for the treatment of disease

Publications (1)

Publication Number Publication Date
SG11201811709WA true SG11201811709WA (en) 2019-01-30

Family

ID=60913147

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811709WA SG11201811709WA (en) 2016-07-06 2017-07-06 Compounds, compositions, and methods for the treatment of disease

Country Status (12)

Country Link
US (2) US11033569B2 (en)
EP (1) EP3481402A4 (en)
JP (3) JP7100227B2 (en)
KR (1) KR102569881B1 (en)
CN (1) CN109843302B (en)
AU (1) AU2017293781B2 (en)
CA (1) CA3029644A1 (en)
IL (1) IL264049B2 (en)
MX (2) MX2019000216A (en)
SG (1) SG11201811709WA (en)
TW (1) TWI689514B (en)
WO (1) WO2018009648A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102530488B1 (en) 2016-03-18 2023-05-08 이뮨 센서, 엘엘씨 Cyclic di-nucleotide compounds and methods of use
IL264049B2 (en) * 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, compositions, and methods for the treatment of disease
JOP20170192A1 (en) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
AR113224A1 (en) 2017-04-28 2020-02-19 Novartis Ag ANTIBODY CONJUGATES INCLUDING A STING AGONIST
PE20210156A1 (en) 2017-11-10 2021-01-26 Takeda Pharmaceuticals Co STING MODULATING COMPOUNDS AND METHODS OF PREPARATION AND USE
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7098748B2 (en) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． 2'3'cyclic dinucleotide with phosphonate binding that activates the STING adapter protein
TWI818007B (en) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
CN111954675A (en) 2018-04-06 2020-11-17 捷克共和国有机化学与生物化学研究所 3'3' -Cyclic dinucleotides
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
US20210309692A1 (en) * 2018-07-10 2021-10-07 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
TW202030199A (en) * 2018-07-17 2020-08-16 美商健生生物科技公司 Cyclic dinucleotides as sting agonists
TWI825170B (en) 2018-09-06 2023-12-11 日商第一三共股份有限公司 Antibody drug conjugates and their applications and uses
BR112021005208A2 (en) 2018-09-21 2021-06-08 Shanghai De Novo Pharmatech Co., Ltd. cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
US11161864B2 (en) 2018-10-29 2021-11-02 Venenum Biodesign, LLC Sting agonists
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
EP3873938A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody conjugates comprising sting agonists
JP7224688B2 (en) * 2019-01-10 2023-02-20 南▲開▼大学 Cyclic dinucleotide prodrug molecules, methods of making and uses thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113543851A (en) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2'3' -cyclic dinucleotides and their prodrugs
KR20210137518A (en) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-cyclic dinucleotides and prodrugs thereof
AU2020267486A1 (en) 2019-05-09 2021-11-11 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as STING modulators
AU2020310853A1 (en) 2019-07-05 2022-01-27 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
EP4115909A1 (en) 2020-03-06 2023-01-11 Daiichi Sankyo Company, Limited Antibody-drug conjugate including novel cyclic dinucleotide derivative
JPWO2021206158A1 (en) 2020-04-10 2021-10-14
CN111909223A (en) * 2020-07-17 2020-11-10 清华大学 Cyclic dinucleotide covalent modifier and preparation method and application thereof
CN116056765A (en) 2020-08-07 2023-05-02 坦伯公司 Trans-cyclooctene bioorthotics and uses in cancer and immunotherapy
CN116113641A (en) 2020-09-02 2023-05-12 第一三共株式会社 Novel endo-beta-N-acetylglucosaminidase
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Antibody drug conjugates

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2257704B (en) * 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
CN102604957B (en) * 2003-06-11 2015-10-07 艾德拉药物股份有限公司 Stable immunomodulatory oligonucleotide
EP1740192B1 (en) * 2004-03-15 2012-06-13 David K. R. Karaolis Cyclic dinucleotide for stimulating the immune of inflammatory response
US7592326B2 (en) * 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
EP2448954A1 (en) * 2009-07-01 2012-05-09 Rutgers, The State University of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
CN102199183B (en) 2010-03-26 2013-12-18 北京大学 C-di-GMP, analogues thereof and preparation method thereof
JP6257607B2 (en) 2012-06-08 2018-01-10 アデュロ バイオテック，インコーポレイテッド Compositions and methods for cancer immunotherapy
EA201590396A1 (en) 2012-12-13 2015-12-30 Адуро Биотек, Инк. COMPOSITION CONTAINING CYCLIC PURINE DYNUCLEOTIDES WITH A SPECIFIC STEREHEMISTRY, AND THE METHOD OF ITS PREPARATION AND APPLICATION
RU2015129030A (en) * 2012-12-19 2017-01-26 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем PHARMACEUTICAL DIRECTED IMPACT ON THE WAY OF TRANSMISSION OF THE SIGNAL OF CYCLIC MAMMAL DYNUCLEOTIDES
JP6243443B2 (en) * 2012-12-20 2017-12-06 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Expression of pattern recognition receptors as a measure of general health
JP6153116B2 (en) * 2013-01-09 2017-06-28 国立大学法人東北大学 Triazole-linked cyclic dinucleotide analogs
EP2762154A3 (en) 2013-02-05 2015-01-21 Nitto Denko Corporation Vaccine composition for transdermal administration
WO2014179760A1 (en) * 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
AP2015008700A0 (en) * 2013-05-18 2015-08-31 Univ California Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
CN103864910B (en) * 2014-03-03 2016-01-20 中国科学院南海海洋研究所 The shellfish pattern recognition receptors LRRP of a kind of novel specific combination LPS
NZ725006A (en) 2014-03-12 2019-11-29 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
AU2015270640B2 (en) 2014-06-04 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of STING
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
CN107148424B (en) * 2014-12-16 2021-01-08 凯拉治疗股份公司 Cyclic dinucleotides for inducing cytokines
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112017018908A2 (en) 2015-03-10 2018-04-17 Aduro Biotech, Inc. compositions and methods for activating interferon gene stimulator-dependent signaling
EP3344644A4 (en) 2015-08-13 2019-02-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
CA3002236A1 (en) 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
MX363780B (en) * 2015-12-03 2019-04-03 Glaxosmithkline Ip Dev Ltd Cyclic purine dinucleotides as modulators of sting.
CN106540260A (en) 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 Interferon gene stimulatory protein(SP)（STING）Application of the agonist in anti-alzheimer's disease
WO2017106740A1 (en) 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
CN109451740B (en) 2016-01-11 2022-09-02 先天肿瘤免疫公司 Cyclic dinucleotides for the treatment of disorders associated with STING activity, such as cancer
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
AU2017225769B2 (en) 2016-03-02 2023-01-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
IL264049B2 (en) * 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, compositions, and methods for the treatment of disease
WO2018045204A1 (en) 2016-08-31 2018-03-08 Ifm Therapeutics, Inc Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
RS62410B1 (en) 2016-10-04 2021-10-29 Merck Sharp & Dohme Benzo[b]thiophene compounds as sting agonists
JOP20170192A1 (en) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
JP2020503303A (en) 2016-12-20 2020-01-30 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Cyclic dinucleotide STING agonists for the treatment of cancer
RU2019122602A (en) 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT
US10933078B2 (en) 2017-02-21 2021-03-02 Board Of Regents, The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
JP2020524718A (en) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ Heterocyclic small molecule regulator of human STING
JP2020524717A (en) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ Small molecule regulator of human STING
AU2018288018C1 (en) 2017-06-22 2022-10-20 Curadev Pharma Limited Small molecule modulators of human STING
WO2019051489A1 (en) * 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease

Also Published As

Publication number Publication date
KR20190032408A (en) 2019-03-27
US20190262372A1 (en) 2019-08-29
US11033569B2 (en) 2021-06-15
AU2017293781A1 (en) 2019-02-07
IL264049A (en) 2019-01-31
JP2022106989A (en) 2022-07-20
CN109843302B (en) 2022-11-29
JP2019532084A (en) 2019-11-07
JP7100227B2 (en) 2022-07-13
IL264049B2 (en) 2023-11-01
TW201805295A (en) 2018-02-16
CN109843302A (en) 2019-06-04
WO2018009648A1 (en) 2018-01-11
EP3481402A4 (en) 2020-01-22
KR102569881B1 (en) 2023-08-22
MX2022006260A (en) 2022-06-29
EP3481402A1 (en) 2019-05-15
IL264049B1 (en) 2023-07-01
JP2023182645A (en) 2023-12-26
US20220054523A1 (en) 2022-02-24
AU2017293781B2 (en) 2022-12-22
TWI689514B (en) 2020-04-01
CA3029644A1 (en) 2018-01-11
MX2019000216A (en) 2019-11-12
US11744845B2 (en) 2023-09-05

Similar Documents

Publication Publication Date Title
SG11201811709WA (en) Compounds, compositions, and methods for the treatment of disease
SG11201900154VA (en) Compounds, compositions, and methods for the treatment of disease
SG11201907820SA (en) Inhibitors of (alpha-v)(beta-6) integrin
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201804915RA (en) Methods for treating huntington's disease
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201407873RA (en) Endoscopic sympathectomy systems and methods
SG11201900501RA (en) Cannabis composition
SG11201909009TA (en) Catheter securement device with window
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201909561RA (en) Octree-based convolutional neural network
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201900665VA (en) Cannabis composition
SG11201909003YA (en) Integrated vascular access device and anchor pad
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201903202VA (en) Osmotic membrane
SG11201805755SA (en) Methods of administering hepcidin
SG11201810192TA (en) Antibacterial compositions
SG11201909107YA (en) Stenosis treatment
SG11201809474TA (en) Compositions and methods for bioengineered tissues